GLP-1s and Gallstones: What the Risk Really Is

GLP-1s are associated with a modest increase in gallstone risk, but most of that risk traces to rapid weight loss rather than the drug acting directly on the gallbladder. Losing weight fast, which GLP-1 medications like Ozempic or Wegovy (semaglutide) and Mounjaro or Zepbound (tirzepatide) are very good at producing, raises the cholesterol saturation of bile, and that is the classic setup for stones. The absolute risk stays low, the main lever you control is the pace of your loss, and the most important thing is knowing the warning signs so you can act on them.

This article explains how much of the gallbladder risk is the drug versus the weight loss, what symptoms to watch for, and how a steadier approach can lower your odds, without framing this as a reason to avoid an effective medication.

How big is the risk, really

It helps to separate the relative risk from the absolute risk, because they tell different stories.

On the relative side, a 2022 meta-analysis in JAMA Internal Medicine found that GLP-1 receptor agonist use was associated with a relative risk of roughly 1.37 for gallbladder and biliary disease, with the risk higher at higher doses (relative risk around 1.56) and with longer treatment duration. So statistically, the risk is elevated.

On the absolute side, the numbers stay small. In the Wegovy semaglutide trials, gallstones (cholelithiasis, the medical term for stones in the gallbladder) were reported in about 1.6 percent of people on semaglutide versus 0.7 percent on placebo. That is roughly a doubling, but from a low base, so most people will not develop stones. The honest framing is "a real but relatively low-incidence risk worth understanding," not a reason for alarm.

Why it happens: weight loss first, drug second

The dominant driver is rapid weight loss itself, and this is not unique to GLP-1s. Any fast, large weight loss (very low-calorie diets, bariatric surgery) carries the same gallstone risk for the same reason: when you lose weight quickly, your liver releases more cholesterol into bile, the bile becomes supersaturated, and cholesterol can crystallize into stones.

GLP-1s may add a second mechanism on top. Research suggests these drugs can reduce gallbladder contractility, partly by altering cholecystokinin signaling (the hormone that tells the gallbladder to squeeze and release bile). When the gallbladder empties less forcefully, bile sits longer, and stasis gives crystals more time to form.

Both mechanisms point to the same practical conclusion. The drug is excellent at producing the rapid weight loss that drives most of the risk, so the pace of loss is the thing to manage. This is the same logic that runs through how fast you should lose weight on a GLP-1: faster is not automatically better.

The symptoms to watch for, and when to seek care

This is the part to actually remember. Knowing the warning signs of a gallbladder attack means you can get help early instead of dismissing it.

The classic symptom is pain in the upper-right area of your abdomen (just under the ribs), often triggered by a fatty meal, which can be sharp and may radiate to your back or right shoulder blade. It can come with nausea and vomiting. A typical gallbladder attack builds over minutes and can last from under an hour to several hours.

Some symptoms point to a more serious complication and warrant prompt medical care. Seek medical care if you have:

• Severe or persistent upper-right or upper-middle abdominal pain.
• Fever or chills along with the pain.
• Yellowing of the skin or the whites of your eyes (jaundice).
• Dark urine or pale, clay-colored stools.
• Pain with repeated vomiting that keeps you from keeping fluids down.

These can signal an inflamed gallbladder or a blocked bile duct, which are medical situations, not wait-and-see ones. When in doubt about severe abdominal pain, get evaluated. This is not about fear; it is about recognizing a treatable problem quickly.

The levers you can actually pull

You cannot make yourself immune to gallstones, but a few habits stack the odds in your favor, and they happen to be the same habits that protect your muscle.

• Keep the pace steady. Crash-losing weight is the single biggest gallstone accelerant. A more gradual rate of loss is gentler on the gallbladder, and it also preserves more lean mass, the topic of how much muscle you lose on Ozempic.
• Don't go fat-free. Some dietary fat in your meals prompts the gallbladder to contract and empty rather than letting bile stagnate. Ultra-low-fat crash diets can paradoxically make gallbladder problems more likely.
• Hit your protein. Adequate protein supports the overall quality of weight loss and is the main lever protecting muscle in a deficit.

That last cluster is exactly why pace and nutrition tracking matter. In Myo, you can watch your rate of weight loss over time and keep it in a steadier range, which protects both your gallbladder and the muscle underneath, instead of crash-losing both at once. Logging weight, body composition trends, and protein lives across Myo's free and Premium tiers, and the rate-of-loss view connects to the recomposition metrics in body recomp on a GLP-1. Myo is a tracking and education tool, not medical advice, and it cannot diagnose a gallbladder problem; that is what your clinician and the symptom list above are for.

The bottom line

GLP-1s modestly raise gallstone risk, but the risk is driven mostly by rapid weight loss, the absolute incidence stays low, and pace is the lever you control. Aim for a steadier rate of loss, keep some fat and plenty of protein in your meals, and above all learn the warning signs: upper-right abdominal pain, especially after fatty food, and the red flags of fever, jaundice, or dark urine that mean you should seek medical care now. Handled that way, this is a know-the-symptoms issue, not a reason to skip an effective medication. Decisions about whether to stop or change a medication belong with your prescriber, not a blog.

References

• GLP-1 and biliary disease relative risk: meta-analysis, JAMA Internal Medicine, 2022 (PubMed 35344001).
• Gallstone incidence in semaglutide trials (1.6 percent vs 0.7 percent placebo): Wegovy clinical trial safety data (Novo Nordisk medlink).
• Mechanism (rapid weight loss raising biliary cholesterol; reduced gallbladder contractility via cholecystokinin): gallbladder/GLP-1 review, 2025 (PMC12739101).
• Lean-mass loss and rate-of-loss context: SURMOUNT-1 DEXA substudy, Diabetes, Obesity and Metabolism, 2025 (doi:10.1111/dom.16275); obesity medicine rate-of-loss heuristics.